3Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance:evidence for a common antecedent? Diabetes Care, 1999,22( Suppl. 3) : C25 -C30.
4Monami M, Marchionni N. IDF and ATP-Ⅲ definitions of metabolic syndrome in the prediction of all-cause mortality in type 2 diabetic patients. Diabetes Obes Metab, 2007,9: 350- 353.
5Qiao Q. Gao W. Metabolic syndrome and cardiovascular disease. Ann Clin Biochem,2007,44(Pt 3) :232-263.
6Grundy SM,Cleeman JI,Daniels SR,et al. Diagnosis and management of the metabolic syndrome:an American Heart Association/National Heart, Lung, and blood institute scientific statement. Circulation, 2005,112 : 2735-2752.
8van Zweieten PA, Mancia G. Background and treatment of metabolic syndrome: a therapeutic challenge. Semin Cardiothorac Vasc Anesth,2006,10:206-214.
9Yki-Jarvinen H. Thiazolidinediones. N Engl J Med, 2004,351 : 1106-1118.
10Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROACTIVE Study (PROspective pioglitAzone Clinical Trial in macroVascular Events) : a randomised controlled trial. Lancet, 2005,366 : 1279-1289.
